This content is from: Patents
The PTAB, pharmaceutical patents and reverse payments
The authors of a new white paper believe that almost 75% of pharmaceutical patent settlements at the Patent Trial and Appeal Board meet the criterion for inferring a strong likelihood of reverse payment settlement. The paper also suggests a rule to deter attempts to exploit the Board as a holdup device as well as discussing reverse patent trolls
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here